Searched for
CIPLA INSULIN
Cipla appoints health chief Shivam Puri to lead One India businessCipla has appointed Shivam Puri as the new Chief Executive Officer for its One India Business. This significant leadership change will take...- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Cipla launches inhalable insulin for diabetes careCipla has launched a new orally inhaled insulin powder for diabetes patients in India. This needle-free alternative to injections offers a ...
- Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COOEris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims ...
- Domestic drug companies in a sweet spot as global players look beyond insulinIndian drug cos are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin...
- Sweet Surrender: Sanofi puts star insulin brand Lantus up for sale, eyes Rs 2,000 cr from Indian pharma giantsSanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licens...
- Cipla shares in focus after receiving CDSCO nod to launch inhalation insulinCipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers ...
- Cipla gets CDSCO nod to launch inhalation insulinCipla received approval from CDSCO to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers ...
- Cipla scales up offerings, investments as it eyes global lung specialty leadershipDrugmaker Cipla said it is scaling up offerings and expanding access to medicines, inhaler devices, diagnostics, as it aspires to become th...
- Cipla expects sales of branded generics to cross $1 billion this fiscalCipla's branded generics business reported sales of around ₹6,000 crore in FY21. The drug maker's India business, which consists of prescri...
- Cipla to sell Lilly's Trulicity, Humalog diabetes treatments in IndiaThis will allow Cipla to expand access to the drugs in the country with the second-highest number of diabetic people in the world. India ha...
- Biocon’s $1-billion biologics sales target ‘looks lofty’Access in healthcare medication is a big concern globally and insulin prices have been soaring in recent years.
- Cipla’s inhalable insulin fails to get approval for trials on Indian patientsCipla had based its application to the panel on the bioequivalence studies with Exubra, an inhalation drug and device combination that was ...
- India's diabetes drugs market grew 22% at $700 million in FY12The domestic diabetes drugs market for FY 12 grew 22 per cent at $ 700 million, according to a Credit Suisse report.
- Wockhardt, Biocon allowed to raise Insulin prices by 18%NPPA has slashed the price of anti-asthma bulk drug used in popular brands such as Cipla's Asthalin, by 18% to Rs 3,633 per kg.
- Very bullish on Glenmark: Aunali Rupani, ARM ResearchNext 5 years will see a big run up in all the pharma stocks in India especially R&D.
- Pharma cos to hike insulin prices by up to 15%Drug price regulator National Pharmaceutical Pricing Authority allows cos to up MRP of popular insulin brands by 15%.
- NPPA cuts prices of three bulk drugs; Cipla, GSK to take a hitNPPA has reduced the price of salbutamol sulphate by almost 6% to Rs 4,478 per kg from Rs 4,748 per kg.
- Budget may bring back duty on insulin importsThe Rs 300-crore domestic insulin industry may get a reverse compliment from the government in Budget 2003.
Load More
